The estimated Net Worth of Karim Mikhail is at least $190 millier dollars as of 31 January 2023. Mr Mikhail owns over 207,700 units of Amarin Corp stock worth over $190,266 and over the last 3 years he sold AMRN stock worth over $0.
Mr has made over 5 trades of the Amarin Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 207,700 units of AMRN stock worth $122,543 on 31 January 2023.
The largest trade he's ever made was exercising 207,700 units of Amarin Corp stock on 31 January 2023 worth over $122,543. On average, Mr trades about 55,917 units every 66 days since 2021. As of 31 January 2023 he still owns at least 322,484 units of Amarin Corp stock.
You can see the complete history of Mr Mikhail stock trades at the bottom of the page.
Karim Mikhail is the Pres, CEO & Director at Amarin Corp.
Mr Mikhail is 50, he's been the Pres et CEO & Director of Amarin Corp since . There are 14 older and 2 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.
Karim's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.
Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum et David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.
amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.
Amarin Corp executives and other stock owners filed with the SEC include: